Mehdi Touat

6.8k total citations · 1 hit paper
74 papers, 2.1k citations indexed

About

Mehdi Touat is a scholar working on Genetics, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mehdi Touat has authored 74 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Genetics, 24 papers in Oncology and 22 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mehdi Touat's work include Glioma Diagnosis and Treatment (48 papers), Radiomics and Machine Learning in Medical Imaging (12 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Mehdi Touat is often cited by papers focused on Glioma Diagnosis and Treatment (48 papers), Radiomics and Machine Learning in Medical Imaging (12 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Mehdi Touat collaborates with scholars based in France, United States and Germany. Mehdi Touat's co-authors include Ahmed Idbaïh, Marc Sanson, Keith L. Ligon, Jean‐Charles Soria, Sophie Postel‐Vinay, Ecaterina Ileana, Fabrice André, Dimitri Psimaras, Johanna Mondésir and Stéphane de Botton and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Bioinformatics.

In The Last Decade

Mehdi Touat

68 papers receiving 2.1k citations

Hit Papers

Glioblastoma targeted therapy: updated approaches from re... 2017 2026 2020 2023 2017 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Glioblastoma targeted therapy: updated approaches from recent biological insights
    2017 322 citations Mehdi Touat, Ahmed Idbaïh et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mehdi Touat France 19 835 800 688 444 440 74 2.1k
Benoît Lhermitte France 18 821 1.0× 1.1k 1.4× 710 1.0× 647 1.5× 702 1.6× 77 2.5k
Christopher E. Pelloski United States 17 1.1k 1.3× 847 1.1× 532 0.8× 540 1.2× 439 1.0× 35 2.2k
Barbara Klink Germany 25 1.0k 1.3× 855 1.1× 530 0.8× 775 1.7× 370 0.8× 73 2.5k
Michael H. Handler United States 29 1.1k 1.4× 1.0k 1.3× 407 0.6× 435 1.0× 328 0.7× 58 2.4k
Jennifer S. Yu United States 24 1.2k 1.4× 823 1.0× 869 1.3× 569 1.3× 826 1.9× 91 2.6k
Carmen Balañá Spain 25 839 1.0× 1.2k 1.6× 774 1.1× 644 1.5× 848 1.9× 119 2.7k
Sridhar Epari India 23 599 0.7× 783 1.0× 288 0.4× 293 0.7× 360 0.8× 198 1.9k
Matthias Holdhoff United States 27 596 0.7× 821 1.0× 604 0.9× 267 0.6× 348 0.8× 111 2.1k
Matteo Simonelli Italy 27 439 0.5× 818 1.0× 691 1.0× 265 0.6× 823 1.9× 129 2.5k
Andreas M. Stark Germany 24 681 0.8× 833 1.0× 850 1.2× 415 0.9× 919 2.1× 47 2.4k

Countries citing papers authored by Mehdi Touat

Since Specialization
Citations

This map shows the geographic impact of Mehdi Touat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mehdi Touat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mehdi Touat more than expected).

Fields of papers citing papers by Mehdi Touat

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mehdi Touat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mehdi Touat. The network helps show where Mehdi Touat may publish in the future.

Co-authorship network of co-authors of Mehdi Touat

This figure shows the co-authorship network connecting the top 25 collaborators of Mehdi Touat. A scholar is included among the top collaborators of Mehdi Touat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mehdi Touat. Mehdi Touat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Touat, Mehdi, Patrick R. Benusiglio, Philipp Euskirchen, et al.. (2025). A Specific Methylation Class Identifies BAP1‐Deficient Meningiomas, Including Meningeal Tumours With Poorly Differentiated Nonrhabdoid Histology. Neuropathology and Applied Neurobiology. 51(5). e70042–e70042. 1 indexed citations
2.
Bellamy, Charlotte, Cynthia Hajal, Keith L. Ligon, & Mehdi Touat. (2025). Revisiting an old therapy for new, promising combinations: Biology and perspectives of lomustine in glioma treatment. Neuro-Oncology. 27(12). 3043–3057. 1 indexed citations
3.
Riche, Maximilien, Karima Mokhtari, Franck Bielle, et al.. (2025). Safety and therapeutic impact of stereotactic biopsy in very elderly patients with brain tumors. Journal of neurosurgery. 143(1). 194–203. 2 indexed citations
4.
Houillier, Caroline, Rénata Ursu, Carole Soussain, et al.. (2024). Unveiling the Clinical and Imaging Signatures of Intravascular Lymphoma of the Central Nervous System: A Multicentric Cohort Study. Annals of Neurology. 97(3). 435–448. 2 indexed citations
5.
Wen, Patrick Y., et al.. (2024). MGMT promoter methylation and survival following chemotherapy for WHO grade 4 IDH-mutant astrocytoma. Neuro-Oncology. 26(12). 2388–2390. 2 indexed citations
6.
Bent, Martin J. van den, Ingo K. Mellinghoff, Mehdi Touat, et al.. (2024). 10311- ACT-19 A GLOBAL, RANDOMIZED, DOUBLE-BLINDED, PHASE 3 STUDY OF VORASIDENIB VERSUS PLACEBO IN PATIENTS WITH ADULT-TYPE DIFFUSE GLIOMA WITH AN IDH1/2 MUTATION (INDIGO): UPDATED EFFICACY RESULTS. Neuro-Oncology Advances. 6(Supplement_4). iv9–iv9. 2 indexed citations
7.
Nichelli, Lucia, Bertrand Mathon, Mehdi Touat, et al.. (2024). Incorporation of Edited MRS into Clinical Practice May Improve Care of Patients withIDH-Mutant Glioma. American Journal of Neuroradiology. 46(1). 113–120. 1 indexed citations
8.
Capper, David, Guido Reifenberger, Pim J. French, et al.. (2023). EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection. Neuro-Oncology. 25(5). 813–826. 54 indexed citations
9.
Mathon, Bertrand, Lucia Nichelli, Justine Guégan, et al.. (2023). Hippocampal and neocortical BRAF mutant non‐expansive lesions in focal epilepsies. Neuropathology and Applied Neurobiology. 49(5). 1–865. 1 indexed citations
10.
Mellinghoff, Ingo K., Martin J. van den Bent, Deborah T. Blumenthal, et al.. (2023). KS02.6.A INDIGO: A GLOBAL, RANDOMIZED, DOUBLE-BLINDED, PHASE III STUDY OF VORASIDENIB VERSUS PLACEBO IN PATIENTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1/2 MUTATION. Neuro-Oncology. 25(Supplement_2). ii4–ii5.
11.
Blumenthal, Deborah T., Ingo K. Mellinghoff, Martin J. van den Bent, et al.. (2023). 498O INDIGO: A randomized, double-blinded, phase III study of vorasidenib versus placebo in IDH1 or IDH2 low-grade glioma. Annals of Oncology. 34. S391–S391. 2 indexed citations
12.
Mathon, Bertrand, Lucia Nichelli, Franck Bielle, et al.. (2023). Exploring the mechanism of 18F‐fluorodopa uptake in recurrent high‐grade gliomas: A comprehensive histomolecular‐positron emission tomography analysis. European Journal of Neurology. 31(1). e16093–e16093. 2 indexed citations
13.
Lamba, Nayan, Malia McAvoy, Vasileios K. Kavouridis, et al.. (2022). Short-term outcomes associated with temozolomide or PCV chemotherapy for 1p/19q-codeleted WHO grade 3 oligodendrogliomas: A national evaluation. Neuro-Oncology Practice. 9(3). 201–207. 6 indexed citations
14.
Malinowski, Seth, Mehdi Touat, Jack Geduldig, et al.. (2021). Functional drug susceptibility testing using single-cell mass predicts treatment outcome in patient-derived cancer neurosphere models. Cell Reports. 37(1). 109788–109788. 16 indexed citations
15.
Ammari, Samy, Tarek Assi, Mehdi Touat, et al.. (2021). Machine-Learning-Based Radiomics MRI Model for Survival Prediction of Recurrent Glioblastomas Treated with Bevacizumab. Diagnostics. 11(7). 1263–1263. 14 indexed citations
16.
Amelot, Aymeric, Maximilien Riche, Franck Bielle, et al.. (2020). Efficacy of a Second Brain Biopsy for Intracranial Lesions after Initial Negativity. Journal of Clinical Neurology. 16(4). 659–659. 10 indexed citations
17.
Mellinghoff, Ingo K., Martin J. van den Bent, Jennifer Clarke, et al.. (2020). INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation.. Journal of Clinical Oncology. 38(15_suppl). TPS2574–TPS2574. 11 indexed citations
18.
Knauß, Samuel, Corinna Preuße, Yves Allenbach, et al.. (2019). PD1 pathway in immune-mediated myopathies. Neurology Neuroimmunology & Neuroinflammation. 6(3). e558–e558. 46 indexed citations
19.
Dunn, Ian F., Ziming Du, Mehdi Touat, et al.. (2018). Mismatch Repair Deficiency in High-Grade Meningioma: A Rare but Recurrent Event Associated With Dramatic Immune Activation and Clinical Response to PD-1 Blockade. JCO Precision Oncology. 2018(2). 1–12. 51 indexed citations
20.
Touat, Mehdi, Damien Galanaud, Charles-Siegfried Peretti, et al.. (2017). Acute Frontal Lobe Dysfunction Following Prefrontal Low-Frequency Repetitive Transcranial Magnetic Stimulation in a Patient with Treatment-Resistant Depression. Frontiers in Psychiatry. 8. 96–96. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Benoît Lhermitte Breakdown of academic impact, for papers by Christopher E. Pelloski Breakdown of academic impact, for papers by Barbara Klink Breakdown of academic impact, for papers by Michael H. Handler Breakdown of academic impact, for papers by Jennifer S. Yu Breakdown of academic impact, for papers by Carmen Balañá Breakdown of academic impact, for papers by Sridhar Epari Breakdown of academic impact, for papers by Matthias Holdhoff Breakdown of academic impact, for papers by Matteo Simonelli Breakdown of academic impact, for papers by Andreas M. Stark
Rankless by CCL
2026